A study in 790 men with metastatic hormone-sensitive prostate cancer treated with either androgen deprivation therapy (ADT) only or ADT plus docetaxel shows that quality of life (assessed, for example, using the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire) of those receiving the combination therapy was worse at 3 months but better at 12 months than that of men receiving ADT only. Both patient groups reported a similar minimally changed quality of life over time.
References
Morgans, A. K. et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J. Clin. Oncol. https://doi.org/10.1200/JCO.2017.75.3335 (2018)
Rights and permissions
About this article
Cite this article
Thoma, C. Quality of life during chemohormonal therapy. Nat Rev Urol 15, 263 (2018). https://doi.org/10.1038/nrurol.2018.44
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2018.44